MNKD - マンカインド (MannKind Corporation) マンカインド

 MNKDのチャート


 MNKDの企業情報

symbol MNKD
会社名 MannKind Corp (マンカインド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マンカインド(MannKind Corporation)は開発段階の生物薬剤学企業であり、糖尿病と癌など疾患用の治療薬の発見・開発・商業化に集中する。同社の製品候補AFREZZA(ヒトインスリン)吸入パウダーは、血糖コントロールのための1型や2型糖尿病を患う成人向けの治療用の後期臨床研究段階にあるインスリン。AFREZZA吸入パウダーは、酸性・塩基性度(pH) 感知の有機分子クラスに集中する。AFREZZAはテクノスフィア処方設計技術を利用する。平成23年12月31日現在、同社の製品より収入はない。平成23年12月31日現在、AFREZZA臨床プログラムは、61の異なるAFREZZA研究及び5600以上の成人患者を含まれている。   マンカインドは米国のバイオ医薬品メ―カ―。主に糖尿病疾患の治療薬の発見・開発・製品化に従事。製品候補のAFREZZA(ヒトインスリン)吸入粉末は、I型またはII型糖尿病成人における血糖コントロ―ルを改善する可能性がある。AFREZZAはテクノスフィア製剤技術を利用している。本社はカリフォルニア州。   MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.
本社所在地 25134 Rye Canyon Loop Suite 300 Valencia CA 91355 USA
代表者氏名 Kent Kresa ケント・クレッサ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 818-661-5000
設立年月日 33270
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 192人
url www.mannkindcorp.com
nasdaq_url https://www.nasdaq.com/symbol/mnkd
adr_tso
EBITDA EBITDA(百万ドル) -98.39600
終値(lastsale) 1.71
時価総額(marketcap) 271441752.57
時価総額 時価総額(百万ドル) 304.44680
売上高 売上高(百万ドル) 13.93100
企業価値(EV) 企業価値(EV)(百万ドル) 407.62780
当期純利益 当期純利益(百万ドル) -118.73000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MannKind Corporation revenues increased 42% to $7.4M. Net loss increased 3% to $53.1M. Revenues reflect Net revenue - commercial product sales increase from $2.7M to $7.2M Net revenue - collaboration increase of 19% to $150K. Higher net loss reflects General and Administrative increase of 25% to $42.3M (expense) Interest Exp-Net of Capitalized Interest increase of 51% to $2.2M (expense).

 MNKDのテクニカル分析


 MNKDのニュース

   MannKind Corporation (MNKD) can excel with these strategies  2022/11/23 15:54:00 US Post News
In Tuesday’s session, MannKind Corporation (NASDAQ:MNKD) marked $4.43 per share, up from $4.30 in the previous session. While MannKind Corporation has overperformed by 3.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MNKD fell by -3.90%, with highs and lows ranging from $4.88 to $2.49, whereas […]
   MannKind Corporation (NASDAQ: MNKD) – Analysts’ Revisions Show Sentiment Is Improving  2022/11/23 14:30:00 Stocks Register
MannKind Corporation (NASDAQ:MNKD) traded at $4.43 at close of the session on Tuesday, 11/22/22, made an upward move of 3.02% on its previous day’s price. Looking at the stock we see that its previous close was $4.30 and the beta (5Y monthly) reads 1.70 with the day’s price range being $4.2193 – $4.435. In terms … MannKind Corporation (NASDAQ: MNKD) – Analysts’ Revisions Show Sentiment Is Improving Read More »
   MannKind Is Poised To Turn A Profit And Shares Could Get Cheaper (NASDAQ:MNKD)  2022/11/23 03:57:32 Seeking Alpha
MannKind''s bright future sets it apart from many in the disappointing biotech industry. See why MNKD stock offers growth potential, but also a considerable risk.
   Observations on the MannKind Corporation (NASDAQ:MNKD) Growth Curve  2022/11/16 20:16:00 US Post News
In the current trading session, MannKind Corporation’s (MNKD) stock is trading at the price of $4.28, a fall of -2.62% over last night’s close. So, the stock is trading at a price that is -12.58% less than its 52-week high of $4.89 and 71.69% better than its 52-week low of $2.49. Based on the past […]
   MannKind Corporation (NASDAQ: MNKD) Stock Is Down -71.08% From Its Low: The Uptrend Is Still On  2022/11/15 12:30:00 Stocks Register
The trading price of MannKind Corporation (NASDAQ:MNKD) closed lower on Monday, November 14, closing at $4.26, -2.74% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $4.12 and $4.49. In examining the 52-week price action we see that the stock hit a 52-week high … MannKind Corporation (NASDAQ: MNKD) Stock Is Down -71.08% From Its Low: The Uptrend Is Still On Read More »
   4 Penny Stocks Insiders Are Buying: MannKind, Crexendo And More  2022/03/02 18:19:14 Benzinga
Russian unemployment rate rose to a five-month high of 4.4% in January from 4.3% in the prior month. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Crexendo The Trade: Crexendo, Inc. (NASDAQ: CXDO ) CEO Steven G Mihaylo acquired a total of 3,000 shares at an average price of $4.42. To acquire these shares, it cost $13.25 … Full story available on Benzinga.com
   MannKind Is At Best Speculative  2022/03/01 20:24:56 Seeking Alpha
   MannKind Corporation (MNKD) Q4 2021 Earnings Call Transcript  2022/02/25 05:30:36 The Motley Fool
MNKD earnings call for the period ending December 31, 2021.
   MannKind''s (MNKD) CEO Michael Castagna on Q4 2021 Results - Earnings Call Transcript  2022/02/25 02:37:08 Seeking Alpha
   MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?  2022/02/25 01:21:08 Seeking Alpha
   Take a deep breath  2021/07/19 14:37:33 Diabetic Investor
Yes we know that Monday isnt the normal day to release another version of our Wacky World of Diabetes podcast but this isnt exactly a normal podcast either as we are delighted to welcome Michael Castagna CEO of MannKind to our list of distinguished guest. As longtime subscribers know weve been following MannKind since day [] The post Take a deep breath appeared first on Diabetic Investor .
   Have an attention on: MannKind Corporation (NASDAQ:MNKD), The Williams Companies, Inc. (NYSE:WMB)  2021/07/18 23:05:42 Stock Equity
MannKind Corporation (MNKD) with the stream of -0.90% also noticed, India The Williams Companies, Inc. (WMB) encountered a rapid change of -1.10% in the last hour of trading session. MannKind The post Have an attention on: MannKind Corporation (NASDAQ:MNKD), The Williams Companies, Inc. (NYSE:WMB) appeared first on Stocks Equity .
   Investors Alert (Technical Performance Analysis): Tempest Therapeutics Inc. (NASDAQ:TPST), MannKind Corporation (NASDAQ:MNKD)  2021/07/11 21:18:46 Stock Equity
Tempest Therapeutics Inc. (TPST) with the stream of 49.38% also noticed, India MannKind Corporation (MNKD) encountered a rapid change of -1.23% in the last hour of Fridays trading session. Tempest The post Investors Alert (Technical Performance Analysis): Tempest Therapeutics Inc. (NASDAQ:TPST), MannKind Corporation (NASDAQ:MNKD) appeared first on Stocks Equity .
   Pulmonary Drug Delivery Market In-Depth Analysis Of Competitive Landscape Executive Summary Development Factors 2028-F. Hoffmann-La Roche Ltd., MannKind Corporation, OMRON Corporation  2021/07/08 06:55:42 OpenPR
Pulmonary Drug Delivery Market research report gives insightful analysis of the market along with its comprehensive understanding and its commercial landscape. The report offers market share appraisals for regional and global levels. It gives detailed overview of the parent market.
   Is The Stock Worthy? Sunrun Inc. (NASDAQ:RUN), MannKind Corporation (NASDAQ:MNKD)  2021/07/07 22:25:39 Stock Equity
Sunrun Inc. (NASDAQ:RUN) with the stream of -4.17% also noticed, India MannKind Corporation (NASDAQ:MNKD) encountered a rapid change of -2.49% in the last hour of Wednesdays trading session. Sunrun Inc. The post Is The Stock Worthy? Sunrun Inc. (NASDAQ:RUN), MannKind Corporation (NASDAQ:MNKD) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マンカインド MNKD MannKind Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)